Strategic partnerships Fibralign已established distribution talks with major medical device players (Terumo) and is active in global conferences, presenting clinical findings. Sales opportunities exist in expanding distributor networks and hospital partnerships in regions beyond 18 countries.

Clinical validation BioBridge collagen matrix has 510(k) clearance, CE mark, and KFDA approval, with adoption by leading surgeons. Leverage these approvals to pursue procurement contracts with large health systems and international distributors seeking compliant, proven lymphedema solutions.

Market expansion Recent conference participation (ISL World Congress 2025) and ongoing surgeon end-user engagement indicate growing demand for lymphatic regeneration therapies. Target hospitals, cancer centers, and vascular clinics expanding lymphedema programs.

Clinical engagement Active collaboration with academic and startup ecosystems (Stanford spin-out, StartX, UCSF Rosenman Institute) suggests opportunities to co-market with academic centers and participate in trials or pilot studies to accelerate adoption.

Growth readiness Revenue is under $1M with a lean team; potential scale through expanded distribution partnerships, regional regulatory navigation support, and clinical education programs to drive adoption in new geographies and hospital networks.